Sanofi : Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
Go back to Sanofi : Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma| BANCO SANTANDER S.A. (NYSE: SAN) | Delayed: 14.40 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.40 | 52 Week High | $5.58 | |||
| Open | $14.40 | 52 Week Low | $3.60 | |||
| Day High | $14.40 | P/E | N/A | |||
| Day Low | $14.40 | EPS | $0.00 | |||
| Volume | 215,778 | |||||
| SANOFI (NASDAQ: SNY) | Delayed: 42.59 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $42.59 | 52 Week High | $44.76 | |||
| Open | $42.59 | 52 Week Low | $36.81 | |||
| Day High | $42.59 | P/E | N/A | |||
| Day Low | $42.59 | EPS | $0.00 | |||
| Volume | 9,066 | |||||
